NCT02410902
A Double Blind Randomized Placebo Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin
Associated Conditions
Neurodevelopmental DisabilitiesSponsor
Curemark
This is a Phase III multi-center, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of CM-AT in pediatric patients with autism at all levels of fecal chymotrypsin.
This study is currently enrolling.